{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=15&q=type+2+diabetes",
    "query": {
      "q": "type 2 diabetes",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 6121,
    "total_pages": 613,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=16&q=type+2+diabetes&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=14&q=type+2+diabetes&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T10:05:49.961Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01150981",
      "title": "Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metabolic Syndrome",
        "Insulin Resistance"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Massachusetts, Worcester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 35,
      "start_date": "2006-11",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2012-03-26",
      "last_synced_at": "2026-10-15T10:05:49.961Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01150981"
    },
    {
      "nct_id": "NCT04628481",
      "title": "A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recent Onset type1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Ladarixin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dompé Farmaceutici S.p.A",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "14 Years to 45 Years"
      },
      "enrollment_count": 289,
      "start_date": "2021-01-12",
      "completion_date": "2025-10-21",
      "has_results": true,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-10-15T10:05:49.961Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04628481"
    },
    {
      "nct_id": "NCT01722266",
      "title": "Liraglutide in the Treatment of Type 1 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Liraglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 75 Years · Female only"
      },
      "enrollment_count": 72,
      "start_date": "2012-11-01",
      "completion_date": "2014-12-01",
      "has_results": true,
      "last_update_posted_date": "2024-01-05",
      "last_synced_at": "2026-10-15T10:05:49.961Z",
      "location_count": 1,
      "location_summary": "Williamsville, New York",
      "locations": [
        {
          "city": "Williamsville",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01722266"
    },
    {
      "nct_id": "NCT00461331",
      "title": "Comparison of Insulins Aspart and Lispro in Insulin Pumps",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Insulin Aspart",
          "type": "DRUG"
        },
        {
          "name": "Insulin Lispro",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tulane University Health Sciences Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2004-10",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2021-01-08",
      "last_synced_at": "2026-10-15T10:05:49.961Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00461331"
    },
    {
      "nct_id": "NCT00525577",
      "title": "ANDES-AGI-1067 as a Novel Antidiabetic Agent Evaluation Study",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "AGI-1067",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AtheroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1012,
      "start_date": "2007-08",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2008-02-06",
      "last_synced_at": "2026-10-15T10:05:49.961Z",
      "location_count": 2,
      "location_summary": "Stockbridge, Georgia • San Antonio, Texas",
      "locations": [
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00525577"
    },
    {
      "nct_id": "NCT03406377",
      "title": "Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "OPK-88003",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 113,
      "start_date": "2018-04-02",
      "completion_date": "2019-06-27",
      "has_results": true,
      "last_update_posted_date": "2021-06-15",
      "last_synced_at": "2026-10-15T10:05:49.961Z",
      "location_count": 3,
      "location_summary": "Huntington Park, California • Los Angeles, California • Hialeah, Florida",
      "locations": [
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03406377"
    },
    {
      "nct_id": "NCT03562767",
      "title": "Cognitive Behavioral Therapy for African Americans With Uncontrolled Type-2 Diabetes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Group-based Cognitive Behavioral Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Web-based Cognitive Behavioral Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Usual Care",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2018-12-05",
      "completion_date": "2019-05-30",
      "has_results": true,
      "last_update_posted_date": "2023-08-02",
      "last_synced_at": "2026-10-15T10:05:49.961Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03562767"
    },
    {
      "nct_id": "NCT01101269",
      "title": "Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "ACEI or ARB",
          "type": "DRUG"
        },
        {
          "name": "Lisinopril",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 6,
      "start_date": "2010-02",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2017-05-12",
      "last_synced_at": "2026-10-15T10:05:49.961Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01101269"
    },
    {
      "nct_id": "NCT00923351",
      "title": "Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma",
        "Sarcoma",
        "Rhabdomyosarcoma-Embryonal",
        "Rhabdomyosarcoma- Alveolar",
        "Neuroectodermal Tumors, Primitive, Peripheral"
      ],
      "interventions": [
        {
          "name": "Tumor Purged/CD25 Depleted Lymphocytes",
          "type": "DRUG"
        },
        {
          "name": "Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rhIL-7",
          "type": "DRUG"
        },
        {
          "name": "Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Months",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "19 Months to 35 Years"
      },
      "enrollment_count": 44,
      "start_date": "2007-06-02",
      "completion_date": "2018-05-15",
      "has_results": true,
      "last_update_posted_date": "2018-06-15",
      "last_synced_at": "2026-10-15T10:05:49.961Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00923351"
    },
    {
      "nct_id": "NCT07197775",
      "title": "Post-market SUrveiLlance RegiStry for the Endogenex System (Endogenex PULSE Registry)",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Type 2 Diabetes Mellitus (T2DM)",
        "Type2Diabetes",
        "Diabetes Mellitus, Type 2",
        "Type 2 Diabetes",
        "Diabetes"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Endogenex, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2026-03-11",
      "completion_date": "2032-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-10-15T10:05:49.961Z",
      "location_count": 3,
      "location_summary": "Quincy, Massachusetts • Raleigh, North Carolina • Houston, Texas",
      "locations": [
        {
          "city": "Quincy",
          "state": "Massachusetts"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07197775"
    }
  ]
}